Cancer Family
Childhood Malignant Neoplasm
CI-CAN-00000132Explore in graph →
Pediatric263 active trials1 approved drugs46 evidence items
- NCIt
- C4005
Loading cancer entity…
Cancer Family
CI-CAN-00000132Explore in graph →
Clinical trials
1,178 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (92)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03837899 | Durvalumab and Tremelimumab for Pediatric Malignancies | active not recruiting | Phase 1 / Phase 2 | 50 | AstraZenecaINDUSTRY | 7 | Sep 29, 2026 | clinicaltrials |
| NCT07529808 | Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 164 | BigHat Biosciences, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07346157 |
| Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease(PNOC044) |
| recruiting |
| Phase 1 / Phase 2 |
| 69 |
| Sabine Mueller, MD, PhDOTHER |
| 1 |
| Sep 28, 2026 |
| clinicaltrials |
| NCT03210714 | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 | clinicaltrials |
| NCT07830667 | A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat | not yet recruiting | Phase 1 / Phase 2 | 79 | Children's Oncology GroupNETWORK | 0 | Sep 22, 2026 | clinicaltrials |
| NCT03849651 | TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies | active not recruiting | Phase 2 | 69 | St. Jude Children's Research HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05334823 | A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents | recruiting | Phase 2 | 100 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07819838 | Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations | not yet recruiting | Phase 1 / Phase 2 | 77 | Children's Oncology GroupNETWORK | 0 | Sep 15, 2026 | clinicaltrials |
| NCT07000253 | Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma(OMEC-5) | recruiting | Phase 2 | 290 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 3 | Sep 10, 2026 | clinicaltrials |
| NCT05849662 | A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia | recruiting | Phase 1 / Phase 2 | 58 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05918640 | Lurbinectedin in FET-Fused Tumors(LiFFT) | recruiting | Phase 1 / Phase 2 | 63 | Children's Hospital of PhiladelphiaOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07428993 | Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma | recruiting | Phase 2 | 41 | St. Jude Children's Research HospitalOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT02867592 | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | active not recruiting | Phase 2 | 109 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06528496 | N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma | recruiting | Phase 2 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05504291 | A Study to Give Treatment Inside the Eye to Treat Retinoblastoma | recruiting | Phase 2 | 26 | Children's Oncology GroupNETWORK | 3 | Aug 25, 2026 | clinicaltrials |
| NCT06158828 | Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML(ABCD-NK) | recruiting | Phase 1 / Phase 2 | 68 | Washington University School of MedicineOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07770698 | A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia | not yet recruiting | Phase 1 / Phase 2 | 30 | BeOne MedicinesINDUSTRY | 0 | Aug 18, 2026 | clinicaltrials |
| NCT03136146 | Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia | recruiting | Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07749976 | GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 108 | VitruviaeINDUSTRY | 0 | Aug 6, 2026 | clinicaltrials |
| NCT07680439 | Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG). | recruiting | Phase 2 | 75 | BrainChild Bio, IncINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06184009 | Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia(HR ALL) | recruiting | Phase 2 | 370 | Jae Wook LeeOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06257394 | Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea(VHR ALL) | recruiting | Phase 2 | 74 | Hyoung Jin KangOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT03155620 | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | active not recruiting | Phase 2 | 1,377 | National Cancer Institute (NCI)NIH | 4 | Jul 24, 2026 | clinicaltrials |
| NCT06458036 | Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)(RAISE) | recruiting | Phase 2 | 13 | Children's Hospital of PhiladelphiaOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07724756 | Phase II Study of QLC2519 in Pediatric Solid Tumor Participants | recruiting | Phase 2 | 18 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT04948619 | Immune Function and Response to Vaccination After Cancer Therapy in Pediatric Patients | recruiting | Phase 2 | 64 | Wake Forest University Health SciencesOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03190915 | Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia | active not recruiting | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Jul 20, 2026 | clinicaltrials |
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2026 | clinicaltrials |
| NCT02813135 | European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors(ESMART) | recruiting | Phase 1 / Phase 2 | 472 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 6 | Jul 10, 2026 | clinicaltrials |
| NCT02094794 | Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML | active not recruiting | Phase 2 | 108 | City of Hope Medical CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04416568 | Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers | active not recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03314974 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | recruiting | Phase 2 | 300 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05754840 | CANnabinoids in Pediatric ONCology(CAN-PONC) | recruiting | Phase 1 / Phase 2 | 60 | University of ManitobaOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05800210 | Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases | recruiting | Phase 2 | 20 | University of FloridaOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07462143 | A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer | recruiting | Phase 2 / Phase 3 | 80 | RemeGen Co., Ltd.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT05468359 | Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients | recruiting | Phase 1 / Phase 2 | 64 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT03286634 | ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016 | active not recruiting | Phase 2 | 60 | National Hospital Organization Nagoya Medical CenterOTHER | 6 | May 11, 2026 | clinicaltrials |
| NCT01920932 | Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma | active not recruiting | Phase 2 | 77 | St. Jude Children's Research HospitalOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04733534 | An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer | active not recruiting | Phase 2 | 110 | St. Jude Children's Research HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05407441 | Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | active not recruiting | Phase 1 / Phase 2 | 49 | Susan Chi, MDOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05735717 | MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies | recruiting | Phase 2 | 70 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07447050 | Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial | recruiting | Phase 2 | 24 | University of California, IrvineOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07437170 | Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML | active not recruiting | Phase 2 | 10 | The Children's Hospital of Zhejiang University School of MedicineOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04134559 | Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma | recruiting | Phase 2 | 18 | Allison O'Neill, MDOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT03938987 | Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)(ACIT001/EXC002) | recruiting | Phase 1 / Phase 2 | 63 | University of AlbertaOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT05634369 | A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue(TINKS) | recruiting | Phase 1 / Phase 2 | 50 | Nationwide Children's HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06208657 | Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer | recruiting | Phase 1 / Phase 2 | 90 | Australian & New Zealand Children's Haematology/Oncology GroupOTHER | 2 | Jan 28, 2026 | clinicaltrials |
| NCT07371663 | An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 266 | Beijing Tide Pharmaceutical Co., LtdINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07334431 | Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer | recruiting | Phase 1 / Phase 2 | 45 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 12, 2026 | clinicaltrials |
Data updated 8 hours agoSource updated Sep 29, 2026source: clinicaltrials